Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study
Pathological outcomes and disease-free survival in KEYNOTE-905: Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible
Characterization of patients responding to enfortumab vedotin plus pembrolizumab (EV+P): exploratory analysis from the phase 3 EV-302 trial of EV+P vs chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
Description and management strategies of prespecified treatment emergent adverse events amongst patients treated with 1L enfortumab vedotin + pembrolizumab for la/mUC in a real-world setting
Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen <0.2 ng/mL despite testosterone recovery after treatment suspension
Overall survival in elderly, frail, or high comorbidity veterans receiving androgen receptor pathway inhibitors with androgen-deprivation therapy vs ADT alone for de novo metastatic castration-sensitive prostate cancer
Real-world outcomes associated with enzalutamide vs apalutamide in metastatic castration sensitive prostate cancer: Analysis of United States Oncology Electronic Health Record data
Trial in progress: Phase 2 study of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients with advanced prostate cancer.
